



NEWS RELEASE

FOR IMMEDIATE RELEASE

INVESTOR CONTACT:

Amy Lynch
Catabasis Pharmaceuticals, Inc.
617-349-1971

Catabasis Pharmaceuticals to Present at Upcoming December Conference

CAMBRIDGE, Mass. – December 6, 2012 – Catabasis Pharmaceuticals, Inc., a clinical stage biopharmaceutical company marshaling its expertise in pathway pharmacology to discover and develop innovative medicines for metabolic and inflammatory diseases, today announced that the Company will present at the following upcoming December conference:

- Oppenheimer 23rd Annual Healthcare Conference, being held Dec. 12-13 at the Waldorf-Astoria in New York, New York. Michael Jirousek, Ph.D., co-founder and chief scientific officer of Catabasis Pharmaceuticals, will give a company overview at 2:10 p.m. ET on Thursday, Dec. 13, 2012.

Catabasis' presentation will be part of the private company track. The presenters at this conference are a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, life science tools and diagnostics, health technology and distribution, provider and service industries.

About Catabasis Pharmaceuticals

Catabasis is a clinical-stage company utilizing its expertise in pathway pharmacology to develop a robust pipeline of innovative medicines for metabolic and inflammatory diseases. These therapies are derived from the Company's SMART Linker technology platform and exhibit mechanistic synergy on the targeted disease pathway. The Company's lead program, CAT-1004, a proprietary new chemical entity, is a SMART Linker conjugate of known active agents salicylate and docosahexaenoic acid (DHA), an omega 3 fatty acid, and targets NF-kB, a multiprotein complex regulating the transcription of both pro-inflammatory and anti-inflammatory factors. The Company's CAT-2003 program is a SMART Linker conjugate of known active agents niacin and eicosapentaenoic acid (EPA), an omega-3 fatty acid, and targets the lipid synthesis pathway. The Company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. Catabasis is headquartered in Cambridge, Mass. Please visit <http://www.catabasispharma.com> for more information.

###